Cargando…

Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting

Cancer is a major threat to the health of humans. Recently, various natural products including curcumin (CCM) have attracted enormous interest for efficacious cancer therapy. However, natural therapeutic agents still encounter certain challenges such as rapid clearance, low bioavailability, and poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Shengli, Wu, Yuesong, Fan, Qingze, Yang, Gang, Hu, Haiyang, Tima, Singkome, Chiampanichayakul, Sawitree, Anuchapreeda, Songyot, Wu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783179/
https://www.ncbi.nlm.nih.gov/pubmed/36559108
http://dx.doi.org/10.3390/pharmaceutics14122614
_version_ 1784857516130172928
author Wan, Shengli
Wu, Yuesong
Fan, Qingze
Yang, Gang
Hu, Haiyang
Tima, Singkome
Chiampanichayakul, Sawitree
Anuchapreeda, Songyot
Wu, Jianming
author_facet Wan, Shengli
Wu, Yuesong
Fan, Qingze
Yang, Gang
Hu, Haiyang
Tima, Singkome
Chiampanichayakul, Sawitree
Anuchapreeda, Songyot
Wu, Jianming
author_sort Wan, Shengli
collection PubMed
description Cancer is a major threat to the health of humans. Recently, various natural products including curcumin (CCM) have attracted enormous interest for efficacious cancer therapy. However, natural therapeutic agents still encounter certain challenges such as rapid clearance, low bioavailability, and poor tumor targeting. Recently, the platelet membrane (PM) camouflaged nanoparticle has provided a promising solution for cancer targeting therapy. Nevertheless, only limited efforts have been dedicated to systematically explore the mechanism of affinity between PM bioinspired nanoparticles and various tumor cells. Herein, a CCM-encapsulated platelet membrane biomimetic lipid vesicle (CCM@PL) with a size of 163.2 nm, zeta potential of −31.8 mV and encapsulation efficiency of 93.62% was developed. The values of the area under the concentration-time curve and mean residence time for CCM@PL were 3.08 times and 3.04 times those of CCM, respectively. Furthermore, this PM biomimetic carrier showed an excellent affinity against Huh-7, SK-OV-3 and MDA-MB-231 cell lines due to the biomolecular interaction between P-selectin on the PM and tumoral CD44 receptors. In addition, CCM@PL displayed enhanced cytotoxicity compared with free CCM and the synthetic formulation. Overall, our results suggest that this developed PM biomimetic lipid nanovector has great potential for targeted cancer treatment and natural components delivery.
format Online
Article
Text
id pubmed-9783179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97831792022-12-24 Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting Wan, Shengli Wu, Yuesong Fan, Qingze Yang, Gang Hu, Haiyang Tima, Singkome Chiampanichayakul, Sawitree Anuchapreeda, Songyot Wu, Jianming Pharmaceutics Article Cancer is a major threat to the health of humans. Recently, various natural products including curcumin (CCM) have attracted enormous interest for efficacious cancer therapy. However, natural therapeutic agents still encounter certain challenges such as rapid clearance, low bioavailability, and poor tumor targeting. Recently, the platelet membrane (PM) camouflaged nanoparticle has provided a promising solution for cancer targeting therapy. Nevertheless, only limited efforts have been dedicated to systematically explore the mechanism of affinity between PM bioinspired nanoparticles and various tumor cells. Herein, a CCM-encapsulated platelet membrane biomimetic lipid vesicle (CCM@PL) with a size of 163.2 nm, zeta potential of −31.8 mV and encapsulation efficiency of 93.62% was developed. The values of the area under the concentration-time curve and mean residence time for CCM@PL were 3.08 times and 3.04 times those of CCM, respectively. Furthermore, this PM biomimetic carrier showed an excellent affinity against Huh-7, SK-OV-3 and MDA-MB-231 cell lines due to the biomolecular interaction between P-selectin on the PM and tumoral CD44 receptors. In addition, CCM@PL displayed enhanced cytotoxicity compared with free CCM and the synthetic formulation. Overall, our results suggest that this developed PM biomimetic lipid nanovector has great potential for targeted cancer treatment and natural components delivery. MDPI 2022-11-26 /pmc/articles/PMC9783179/ /pubmed/36559108 http://dx.doi.org/10.3390/pharmaceutics14122614 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wan, Shengli
Wu, Yuesong
Fan, Qingze
Yang, Gang
Hu, Haiyang
Tima, Singkome
Chiampanichayakul, Sawitree
Anuchapreeda, Songyot
Wu, Jianming
Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
title Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
title_full Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
title_fullStr Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
title_full_unstemmed Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
title_short Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
title_sort bioinspired platelet-like nanovector for enhancing cancer therapy via p-selectin targeting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783179/
https://www.ncbi.nlm.nih.gov/pubmed/36559108
http://dx.doi.org/10.3390/pharmaceutics14122614
work_keys_str_mv AT wanshengli bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT wuyuesong bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT fanqingze bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT yanggang bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT huhaiyang bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT timasingkome bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT chiampanichayakulsawitree bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT anuchapreedasongyot bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting
AT wujianming bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting